All News
Filter News
Found 2,237 articles
-
Senda Biosciences Appoints MIT Institute Professor Paula Hammond, Ph.D., to Its Board of Directors
12/14/2022
Senda Biosciences, Inc. announced the appointment of Paula Hammond, Ph.D., Institute Professor and Head of MIT's Department of Chemical Engineering, to the Company's Board of Directors.
-
An investigational mRNA cancer vaccine developed by Moderna and Merck reached its primary efficacy endpoint, inducing a clinically meaningful improvement in recurrence-free survival.
-
Flagship Pioneering Unveils Montai Health to Treat and Preempt Chronic Disease Afflicting Two Billion People Worldwide
12/13/2022
Flagship Pioneering, the bioplatform innovation company, unveiled Montai Health, a company unlocking the power of nature with its CONECTA™ platform to create medicines that treat and preempt a broad range of chronic diseases.
-
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
12/13/2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940.
-
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
12/12/2022
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease.
-
Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age
12/8/2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children 6 months through 5 years of age.
-
Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age
12/8/2022
Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 vaccines to include use in children down to 6 months of age.
-
In the heated race for a new respiratory syncytial virus vaccine for older adults, Pfizer gained ground on GSK after winning priority review designation for its vaccine candidate.
-
Brad Miller Joins Moderna as Chief Information Officer
12/7/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced the appointment of Brad Miller as Chief Information Officer effective January 3.
-
Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin’s Gold Medal and Rising Star Respectively
12/7/2022
The Sabin Vaccine Institute honored two extraordinary scientists for their breakthrough vaccine research that changed the course of the COVID-19 pandemic, advanced public health, and saved countless lives.
-
Home to many of the world's leading life science companies, the Genetown hotbed is a hub of activity. To help you in your job search, here are 10 Massachusetts biopharma companies hiring now.
-
Quris Appoints Henry McKinnell as Chairman of Newly Established Advisory Board
11/30/2022
Industry Luminary Brings Pharmaceutical and Financial Leadership to Team of Influential Experts Guiding BioAI Innovator’s Continued Growth
-
mRNA Synthesis Raw Materials Market Size, Trends, Share, Growth | Report 2022-2030
11/28/2022
mRNA is synthesized in the nucleus with the use of a template made up of a DNA nucleotide sequence.
-
Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics
11/21/2022
Nona Biosciences announced that it has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona's proprietary fully human heavy chain only antibody transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.
-
Pfizer and BioNTech reported positive data Friday from their Omicron BA.4/BA.5-adapted bivalent booster. This followed a similar announcement by Moderna Monday.
-
RSV, influenza, COVID-19 and monkeypox have dominated vaccine discussions this year, but vaccines are also being developed for a host of other infectious diseases.
-
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
-
Precision Oncology Market Size up to 2030 - Quantitative Research by QYResearch Medical
11/15/2022
The global Precision Oncology market is forecasted to grow at a rate of 9.9% from USD 49.98 billion in 2019 to USD 99.72 billion in 2030.
-
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
11/14/2022
Roivant Sciences Ltd. (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2022 and provided an update on the Company’s operations.
-
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
11/14/2022
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three-month and nine-month periods ended September 30, 2022.